more

Clover Health Investments (CLOV)

(Delayed Data from NSDQ)

$4.20 USD

+0.08 (1.94%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $4.20 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

Top 30% (74 out of 250)

Industry: Medical Info Systems

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bear of the Day: Icahn Enterprises (IEP)

by Andrew Rocco Published on June 15,2023

IEP stock is getting crushed this year as an inflated NAV, poor fundamentals, and negative headlines present obstacles.

spac

Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on June 09,2023

Here is how Ligand Pharmaceuticals (LGND) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Is Clover Health Investments (CLOV) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on May 19,2023

Here is how Clover Health Investments, Corp. (CLOV) and Pyxis Oncology, Inc. (PYXS) have performed compared to their sector so far this year.

Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on May 09,2023

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 21.05% and 7.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CLOVPositive Net Change

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on January 05,2023

Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Down 22.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Clover Health Investments, Corp. (CLOV)

by Zacks Equity Research Published on November 10,2022

The heavy selling pressure might have exhausted for Clover Health Investments, Corp. (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

CLOVPositive Net Change

Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 07,2022

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 48.39% and 3.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CLOVPositive Net Change

10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 02,2022

10x Genomics (TXG) delivered earnings and revenue surprises of 17.78% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on August 08,2022

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 4.35% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CLOVPositive Net Change

Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research Published on August 04,2022

Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Signify Health (SGFY) Q2 Earnings Beat Estimates

by Zacks Equity Research Published on August 03,2022

Signify (SGFY) delivered earnings and revenue surprises of 130% and 1.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CLOVPositive Net Change

Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on May 09,2022

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 20.83% and 7.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Clover Health (CLOV) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on May 06,2022

Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on May 04,2022

10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on April 28,2022

Omnicell (OMCL) delivered earnings and revenue surprises of 16.90% and 0.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?